BioWorld

March 22, 2004

Critical Therapeutics Files For Estimated $103.5M IPO

Makeup Of Bush's Bioethics Committee Comes Under Fire

Chiron's Tezacitabine Scrapped After Phase II Trial Misses Goal

Other News To Note

$100M In Private Funds Expected To Expand Neurogen's Portfolio

Neurogen Corp.'s stock rose on Friday, following news that the company entered an agreement to privately sell $100 million worth of common shares. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...